N
Google TrendJONAS BROTHERS (500+) — Jonas Brothers postpone Birmingham concert over weather concerns
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:jonas brothers500+steven kwan500+kings vs warriors200+steffi graf200+boxing200+ben simmons500+lisa500+bill maher500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Safety and Efficacy of IL" (30 stories)

Top Headline Story

Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL
Lead StoryThe ASCO Postgeneral
Aug 3

Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQaUp4bGxFekU0X0tYeXk0SV9qMDVub2JlN1d3MmZtSGtKVkdSZ1pmN1NJWXJKSWZjMGNkOGRQT3pkakRJLTNaMENURGo1WjZ5QWRXMEpwdThQUHpSZFk3WjNHUkxpLUY4QzJfeW9jN1pUbFFCU2ZWVmFFdk4wcks5WXlmYlRScnU1Z0l0MzJTLTlUMy01SDAxV1lZQ1g1UmJyOV9mU3dncDRmOF9SdUxDNzh4cU9XbmNZcjVPUnk4cUNYSXdoLUp5cA?oc=5" target="_blank">Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+21m ago

jonas brothers

Jonas Brothers postpone Birmingham concert over weather concerns

Filter stories
500+21m ago

steven kwan

Guardians' Steven Kwan Could Shake Up Winter Outfield Market

Filter stories
200+21m ago

kings vs warriors

3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings

Filter stories
200+21m ago

steffi graf

PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance

Filter stories

Search Results for "Safety and Efficacy of IL"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
New IL-4 Inhibitor Found Effective for Prurigo Nodularis
Medscapeworld

New IL-4 Inhibitor Found Effective for Prurigo Nodularis

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPVDFMUThubHVSMGlNMU5neEVsQWJRNkFqWFViWW1JTGNGUTJVVzA3cm1MaTZROHF6bWk5R1JCRktVdHowcjlIU2hLay1nMm1ZUmdfZEpPQmt2NlFuNUxyemRUSC1NczFIdGtfTVJhTE9UbnpxQ3I4dFNSSl83cjF0YnNpUVgtOUt2UzFsZ1hZUmtvRkhqM2hlODhpMXR1S2hMellaY3NzcHI4ZjJW?oc=5" target="_blank">New IL-4 Inhibitor Found Effective for Prurigo Nodularis</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases
Frontiersgeneral

Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNNTY1YjczTU95UVZJSDZobDNVWDk5Y3lnSmxaS0RFN0NRaHBUMTVOYTNtU2pONmlXSkowbWN5MksxX09VcDJRcEhucWNYVXJtd3hkNWItaVVucm1BdVRsRHk2dWRaLTljWV9ndUU1a3daSHFjTEt2UUw0b3VhWmRnS2x0Mkw3a2JYV1FWQy1lVVk?oc=5" target="_blank">Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial
Naturegeneral

Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE92Q1R0YUE5MGhid3ZUaE1haWw0bjNDRUJZVXlUb0xndUN6QkhkVGxwZm1lR0VhWU5lemhFX1d5ZDVSUXpsQXQwQWsteU14YmlRYjN4WGwxNlQwM2hLQkNr?oc=5" target="_blank">Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
IL-23p19 Inhibitors Show Superior Drug Survival for Effectiveness and Safety in Psoriasis Compared to IL-17 and Other Biologics: BADBIR Cohort Study
Vera Healthgeneral

IL-23p19 Inhibitors Show Superior Drug Survival for Effectiveness and Safety in Psoriasis Compared to IL-17 and Other Biologics: BADBIR Cohort Study

<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE9HSkRkYW1kRUlfSEtMclNteVg4dTlIb0hZMDZkc0RTRS0yTzU3Nml4SllTWENoaXp1RGhlYXIyR2xPLU96VXZFYlJGWjVUOWM?oc=5" target="_blank">IL-23p19 Inhibitors Show Superior Drug Survival for Effectiveness and Safety in Psoriasis Compared to IL-17 and Other Biologics: BADBIR Cohort Study</a>  <font color="#6f6f6f">Vera Health</font>

Read Full StoryMore like this
Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial
Naturegeneral

Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9PX2Eya19nN2hudE95cWRmcWVWSHZvdEhFMWU0LUdicGtGQ3B6a3dtVndfWGFuWk9QTDBpSy1VWlpqc0tBSDhpNlFuZ0JMR2NDRG5CR2lpWHNFQ2pvcjFN?oc=5" target="_blank">Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders
Frontiersworld

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOWFpORC1iejZOLXZrUUJmR3NnU3FqMEUxWjdIaXRKQm5ROUtGWHdHRFpWYnBjdnpqUjRUVFlsMDVZTlZnNnVhOHNRdXhBNExBNjNHX00yNndLZ0dJR2E1aklaSEFFZ2k1MDhwXzVZVF81TXN6TmVnUUJCbUVyZl9mblFmcTdQY2VpdmpPdC14X1Q?oc=5" target="_blank">Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial
The Lancetgeneral

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPVGZpOEJmcjlacllaLXUyYXJqT0FyaWliUlRUeTYxX05fLTllMTd6Mk1jWWUzR3NwcFF2MDN1eG5EVV84NmUyam5ObDg3N1FjRDFJajB2cXZIbjMzS0NtYnlwdVp0MEV4VlNLbE5iVkx6dVBJM2tnRFB1cUF5bHl1NHZMcGZWR3hvaGZN?oc=5" target="_blank">Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
The New England Journal of Medicinegeneral

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE51Qy04ajdISlI0clIwbnVJa1lDUV9GYWJvb3hnYzlVMXFEZjJxNVAzQWlxdEtON01OZWQ0NjRXcXg4WTJ3VTI3b3N4N1FxVE1MM2sxYjAxd2psdkxUbnloLQ?oc=5" target="_blank">Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma</a>  <font color="#6f6f6f">The New England Journal of Medicine</font>

Read Full StoryMore like this
Efficacy and Safety of IL-23 Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: Systemic Review and Network Meta-Analysis
medRxivgeneral

Efficacy and Safety of IL-23 Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: Systemic Review and Network Meta-Analysis

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTFB5NUw1NGdZc2VqWmZNUEdNWmJhcWpPUlhPTlkta1VNbVc1VVZTUC16SVBFLXo2blVYVjBWNE51dXE4cGpwSGs1MDJIdFRMd1c5enNTcXdnRGpmX3NRLXNxSDlObXlFUmJRNkJua2pjUEJhUQ?oc=5" target="_blank">Efficacy and Safety of IL-23 Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: Systemic Review and Network Meta-Analysis</a>  <font color="#6f6f6f">medRxiv</font>

Read Full StoryMore like this
Nemolizumab Maintains Long-Term Efficacy in AD
Dermatology Timestech

Nemolizumab Maintains Long-Term Efficacy in AD

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPRzRvWFZXYUtmZEM3MFZZSEFheVJhWjZNaGhkM2h3UnZxWTFwOHJJR3J5RW53dUp0MFVYVUlCWEh0TXVSUWs4V2ZfVlhNcFZUT3UwSjZxN2c4bXFIcWxFRjlHZEtJamtiSmFOV0xEZzU4R29tUzgzYk1pYTFUQXdGOWI5SzQtZGpDMlNjQw?oc=5" target="_blank">Nemolizumab Maintains Long-Term Efficacy in AD</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
Efficacy and Safety of Low-Dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: A Systematic Review
Cureusgeneral

Efficacy and Safety of Low-Dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: A Systematic Review

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQdHBnZ19CTGFuYWZQc0pOSk55UlFCLXJpWFFQR1ZDVHdxOE1nQ2tnZWYxZ2t0WHpqNXFPSV91RWRsQUFIbTNjaXE4SjNxSWFNMUtIQTlYWWJHQnh3STFYYlB5Z2JjUVEtcGxweklnVUlZeEdORnlnSHA5SlZCMEFkVG5NV3pyR3liSEN2WHUxRmlETWN6ZjQwYWlBVmd5X3ViWi1LVlhRNjFKSk9rTHhYUTZlVGZCa1g2SG56bWRCd2FkRTU5Sjk5TmthSEJHVmY5U2FUQmFWSkM0Slkx?oc=5" target="_blank">Efficacy and Safety of Low-Dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: A Systematic Review</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
The New England Journal of Medicinegeneral

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9oajBfbks4NTlERmVwbUY4Q0hzbzNCcWZTS3phWVAxZmdiNW1EbFlKMHZXaHY5NUhCWmdBdDB6TFBPXzZ1dFZaelRFanR0cklsbFFMNHpPWWlmMzIyRVRDMw?oc=5" target="_blank">Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis</a>  <font color="#6f6f6f">The New England Journal of Medicine</font>

Read Full StoryMore like this
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial
Naturegeneral

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9mLUdqLTNTaFB3dlU1VXZic1BSd1ltREV3VjNRRVN0cEZqanVsTmVVOHNCRzNlcjdNNlFzUEE0WXdxS1A1MmZDaEV4RGFIUk9EbWIzSjZ4V3hBWGdackdj?oc=5" target="_blank">Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
The New England Journal of Medicineworld

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1LTFJtTmNYZDNFTjI2azIwVjQ2T08ycERNazI2ekNBa0dsUUR3Y3RQMlpDN0xNN2NDdjVQUjZ6Y3g1MVVUNDVWU1R5RVlTWEc3amZwNU9vNS0ybXRXUl9Udw?oc=5" target="_blank">Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma</a>  <font color="#6f6f6f">The New England Journal of Medicine</font>

Read Full StoryMore like this
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19
Naturegeneral

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1YUXJ3Y0ZocU1EczVIVmloOTZ5YmFNWW9ObzFmTVU2OW1CQUxjUENaTzV5M3I3ZVJ3VVpqMXpvT0U5OFhHbVhoWWFLZUUtMWxhVHFkVU9GbVNrQ00tUU5Z?oc=5" target="_blank">Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
Naturegeneral

Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE04VEFKTnZZc1hldkhRMWtmYVphMWJYdXRNMU00QXpIeFpQQ2c4cDVRcnNtaDVNY2RvaFpEVTZhNEM4b05zTERoZ25xek5TaC0xQ3VwVmVlMWRFVElpR01Z?oc=5" target="_blank">Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Naturegeneral

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE80emxRdmUtSGV2ckpON2FPSkRMUjJwSmZWSndOUE9UU3c4cy1ERGhEVmpnSHVsdmtyUEtpZ21HLW11TXBiSUcxeHJzQnhNOWhucHVWMDQ1ZEoxUXF5MENB?oc=5" target="_blank">Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management
Naturegeneral

Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9VWW81cENpcjdQLVpKUktSeklTQUZHdGFoNW9meVpIR0dTZndUZEdsNTd1dlUyUUZxbTVxb1N0ejZHbHBoQ3N5MmRHY2hqeE45Rm1fVXZpbENnQTg5WUo0?oc=5" target="_blank">Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial
Naturegeneral

Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9VU1RFTW1CdEMzODZ2WHhzTEJoSHVDLU02TlByY2E4d2lZTlRyQVZLOUVGSlRGYkdFUlY1SGZjTWlzWGNpVTFnTWhiZWc5UWRVb2pUaERIYzYtRjZqelpr?oc=5" target="_blank">Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis
Frontiersgeneral

Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOUVBQdkVGbWZ5Ui13bW42elZVRC01aGhadEwwRDRXc2EwVE9FLTZlNXBURmhLa2tyMHRsRGxkN1ZIQlBZaGJXUnBtbjF6NllZU19Bd294ZXlKR1lxcHBXTm55NjlIV1BRYkNwZHpPYXZVUHpiSlc4MTlzQmlONHhDeFI1RWdZZ1o3ZmVoOGR0b2s1MEo0?oc=5" target="_blank">Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Safety and Efficacy of IL-17 Blockers for Psoriatic Arthritis
MedPage Todaygeneral

Safety and Efficacy of IL-17 Blockers for Psoriatic Arthritis

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTFBxcF96LUV2QW1tdGVwaGJWS1F0Q25aaTZWRWFrWW1rcl9paGpBejl6Yk1UWjc2dVcwcEczc21qWWFhN2F3NGs1M0Q3NVpfVUxPQUw3N1R4M1F2TndEWjViUllrTHNZOHZFMlJtcVVqQ0VaYXpLZTJkejBVRQ?oc=5" target="_blank">Safety and Efficacy of IL-17 Blockers for Psoriatic Arthritis</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Dermatology Timesgeneral

Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQTmlyb2VKR3pjUlA0d1dDT2V5WUlzSmN3SmtUNndVeVNxLWZIUlJSbUo1S3R5ZG1jR0NHdHZhV2RZUFVWVEJlZjFWZjVLd3E4X053NkF4V1BoZzEzVmNxdndOeW1jME5ZVE1McXlLYUtHcEYxZGN3dTVWVHh0X3RHSi1RQlZxSUVzU3RRS19mTXVVNXBqU1ZjYjNTMVhWQ0JMRUE?oc=5" target="_blank">Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma
OncLivegeneral

Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQdXRjejhNY0ZCbWdTaE10blRvZ3ByeHFnSkloSWZfX0o1T3p4Q3BSZl8yUUx1RllYYmgzQnZLVFVYZnBXdUEweFNGVVBiNHFQSlVSR2xTT2RYRFpxMzVwWU10RVlNM2NKY2VwSnB3VTNnNUlPeGdlMFlvTk4wSXZ4Z3lNZWdpZnFCeUwxTDluODVoUlRtUXJ0ckxZczIwNVB4WHB4YkMxUmM1YlNSMTBsdXV3S1BDamxUQlhiM19n?oc=5" target="_blank">Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Do Anti-IL-6 Receptor Blockers Hold Promise for Relapse Prevention in MOGAD?
Neurology® Journalsgeneral

Do Anti-IL-6 Receptor Blockers Hold Promise for Relapse Prevention in MOGAD?

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE53Sl9jYmZoNnhDYXhpTndTUlZfMTNITkQxTERseThsR2lHb2J1bFZ3M21rZmRsYlNYWU5jU1VtWmw4TTBUQTlOUUx4Q2x4NjZxazUtdmF4cjNMbTdSaVJtdDZTVjhDY0FlaHc?oc=5" target="_blank">Do Anti-IL-6 Receptor Blockers Hold Promise for Relapse Prevention in MOGAD?</a>  <font color="#6f6f6f">Neurology® Journals</font>

Read Full StoryMore like this
A Systematic Review and Meta-analysis of Novel Interleukin Inhibitors' Efficacy and Safety in the Treatment of Psoriatic Arthritis
Physician's Weeklygeneral

A Systematic Review and Meta-analysis of Novel Interleukin Inhibitors' Efficacy and Safety in the Treatment of Psoriatic Arthritis

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxNa3ZKRHBKeWdvSVpfcmxjR3NxOTFaUFdkOFRuMFVVcUdsZE4zcmUyRW05OU1hcmdjOU0xdFNETnBFUUdCRDhHQ3d4OTFVNHMzQUE0U3VpaDhPZHIyTjdvdmJqOVB2aDVnSEhabTJTMUdtalBOTUtBZjhmV2Y0TDBPRTZxbGhlcTBvSHNNdHRvcmdaNkE3MmFKcm9jTG5rb2FyVmFUMW9uclpXWnVSZDR4bzA1aU5ZTFRhM0RfT1F2c0g1ZGdCOGkzcWRkUktTdDB0WHNiMk5JemNETi1rZERENDFBR3IxQS1fa1FpN1IwY1RtcExHOUhVRjBjOA?oc=5" target="_blank">A Systematic Review and Meta-analysis of Novel Interleukin Inhibitors' Efficacy and Safety in the Treatment of Psoriatic Arthritis</a>  <font color="#6f6f6f">Physician's Weekly</font>

Read Full StoryMore like this
Fall Clinical News: Tralokinumab Shows Long-Term Safety and Efficacy in AD
The Dermatology Digestgeneral

Fall Clinical News: Tralokinumab Shows Long-Term Safety and Efficacy in AD

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOdHBWTlpEUFdpT0Z1bEo1N0hRR09Sb3JiNGtPbjJsVFFfcVcxS3JnbE1ySEk4Skg1TElwYlJqX3VhZldSSVpHWE9seTFxbzFNVmxaaGJiZV80Qlg2VkNCbjRPSlJjRlF3TWFSS2k5WHQwNDU3a08wLUMycjQzOTVYeWVVMzRSRUUyWmdpenpSOVhlN0tyX05oeG8tVDJMYndrTFE?oc=5" target="_blank">Fall Clinical News: Tralokinumab Shows Long-Term Safety and Efficacy in AD</a>  <font color="#6f6f6f">The Dermatology Digest</font>

Read Full StoryMore like this
IL-6 Targeting in COVID-19 Treatment
Cleveland Clinicgeneral

IL-6 Targeting in COVID-19 Treatment

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTFB5TThRbDI2TENmdjZzT0ZCZ3Fnek5kSzl0ejZVUGZBZEdDM3hfbVE2QmVNc0VTOVF4N29rUVpyMFFPb2E5TDEtQVZHcG9OMFBaTGp6VW5FZDJSYm5SY1htZVFtZmJfRHdKRUtRUmlHeTNMbmxRbFdZR000UUQ2Y2c?oc=5" target="_blank">IL-6 Targeting in COVID-19 Treatment</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland
Natureworld

Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9jY1ZKV0RIZlZPMk5LSExBUENmMVRMeVNHcmk5MHRxS2x6NVB2RU1jb3ZZbnc4clBXNHd0THpFZ3V2Sm0xNFlqSHJOaWw5c1gxdW1rcHFxck52TE96TExJ?oc=5" target="_blank">Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
New IL-7 Antagonist Lusvertikimab Shows UC Efficacy
Medscapegeneral

New IL-7 Antagonist Lusvertikimab Shows UC Efficacy

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOSmxHOWRQckYyZXBsNEVjNUhUak9VWG5QRDFSUTNXaENtdHBsektGdVNWR3BYR1FaZlU1OWxwXzdDVjJIR0k4eFctM3B4QUJJR1pZZWhYSDZSU2FMakRtaEpnQTFRLUNpaWxsSkRyRGMzMnJMWTBaVTEtMjFSZlg1RVdpY0dXeXRPZGliOGlRTnNZeHFGQ0RBcUFkYnVHVW81YW9R?oc=5" target="_blank">New IL-7 Antagonist Lusvertikimab Shows UC Efficacy</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
"Safety and Efficacy of IL" — Live Google News Trends & Headlines